Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial

• Published in: JAMA network open Vol. 4; no. 2; p. e210369
• Main Authors: Thomas, Suma, Patel, Divyang, Bittel, Barbara, Wolski, Kathy, Wang, Qiuqing, Kumar, Anirudh, Il'Giovine, Zachary J, Mehra, Reena, McWilliams, Carla, Nissen, Steve E, Desai, Milind Y
• Format: Journal Article
• Language: English
• Published: United States American Medical Association 01.02.2021
• Subjects: Acids; Adult; Ambulatory Care; Antioxidants - therapeutic use; Ascorbic Acid - therapeutic use; Clinical trials; Cough - drug therapy; Cough - etiology; COVID-19 - complications; COVID-19 - drug therapy; Dietary Supplements; Dyspnea - drug therapy; Dyspnea - etiology; Fatigue - drug therapy; Fatigue - etiology; Female; Fever - drug therapy; Fever - etiology; Gluconates - therapeutic use; Humans; Infections; Male; Middle Aged; Online Only; Original Investigation; Public Health; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Severity of Illness Index; Standard of Care; Trace Elements - therapeutic use; Treatment Outcome; Zinc - therapeutic use
• ISSN: 2574-3805; 2574-3805
• DOI: 10.1001/jamanetworkopen.2021.0369

There is limited evidence regarding early treatment of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to mitigate symptom progression. To examine whether high-dose zinc and/or high-dose ascorbic acid reduce the severity or duration of symptoms compared with usual care among ambulatory patients with SARS-CoV-2 infection. This multicenter, single health system randomized clinical factorial open-label trial enrolled 214 adult patients with a diagnosis of SARS-CoV-2 infection confirmed with a polymerase chain reaction assay who received outpatient care in sites in Ohio and Florida. The trial was conducted from April 27, 2020, to October 14, 2020. Patients were randomized in a 1:1:1:1 allocation ratio to receive either 10 days of zinc gluconate (50 mg), ascorbic acid (8000 mg), both agents, or standard of care. The primary end point was the number of days required to reach a 50% reduction in symptoms, including severity of fever, cough, shortness of breath, and fatigue (rated on a 4-point scale for each symptom). Secondary end points included days required to reach a total symptom severity score of 0, cumulative severity score at day 5, hospitalizations, deaths, adjunctive prescribed medications, and adverse effects of the study supplements. A total of 214 patients were randomized, with a mean (SD) age of 45.2 (14.6) years and 132 (61.7%) women. The study was stopped for a low conditional power for benefit with no significant difference among the 4 groups for the primary end point. Patients who received usual care without supplementation achieved a 50% reduction in symptoms at a mean (SD) of 6.7 (4.4) days compared with 5.5 (3.7) days for the ascorbic acid group, 5.9 (4.9) days for the zinc gluconate group, and 5.5 (3.4) days for the group receiving both (overall P = .45). There was no significant difference in secondary outcomes among the treatment groups. In this randomized clinical trial of ambulatory patients diagnosed with SARS-CoV-2 infection, treatment with high-dose zinc gluconate, ascorbic acid, or a combination of the 2 supplements did not significantly decrease the duration of symptoms compared with standard of care. ClinicalTrials.gov Identifier: NCT04342728.